المنشور

04:28 AM EST, 11/13/2026 (MT Newswires) -- Berenberg raised its earnings estimates for Novo Nordisk (NOVO-B.CO), while reiterating its hold rating ahead of the expected launch of CagriSema in early 2027. "Novo delivered solid Q3 results; an underlying 5% sales beat prompted a guidance upgrade. Wegovy pill continues to surprise on the upside, and new market launches should see strong growth carry into 2027. However, Novo's injectable business remains lacklustre as competitor Eli Lilly [LLY.SW, LLY.F] continues to dominate market share gains. Investor sentiment on the upcoming CagriSema launch remains subdued. With this rollout, Novo must prove a renaissance in obesity injectables is achievable and that semaglutide patent expiries are surmountable," analysts said Friday. Alongside its third-quarter earnings release, the Danish drugmaker updated its full-year 2026 outlook, expecting adjusted sales and operating profit growth between -2% and +2% at constant exchange rates from the previous projection of -6% to 0%. Against this backdrop, the research firm raised its sales, EBIT and EPS forecasts for 2026 to 2028. Meanwhile, Berenberg left the stock's price target unchanged at 305 Danish kroner. Looking ahead, analysts said expected key catalysts include anticipated US approvals for CagriSema and the high-dose Ozempic pill in the fourth quarter of 2026, alongside phase 3 data for cagrilintide and Redefine-11 trial results for CagriSema in 2027.